General. With the exception of 2-amino-3-benzyl-5-phenylpyrazine that was obtained from InnoChemie GmbH (Würzburg, Germany), all reagents and solvents were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and used without further purification. All 1 H NMR spectra were obtained on a Varian XL-400 (Varian, Palo Alto, CA) at 400 MHz. Electron spray ionization (ESI) mass spectrometry was done by Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University. Absorbance spectra were obtained on Agilent UV-visible Chemstation. Fluorescence spectra were recorded on FluoroMax-3 Jobin Yvon fluorometer. Purification and analysis of the products was performed using the Dionex Summit ® high-performance liquid chromatography (HPLC) system (Dionex Corporation, Sunnyvale, CA), equipped with a 340U 4-Channel UV-Vis absorbance detector. Reverse phase HPLC column Dionex Acclaim®120 (C18, 4.6 mm × 250 mm) was used for the analysis of the products. The mobile phase was 0.1% trifluoroacetic acid (TFA) in water and 0.1% TFA in acetonitrile (CH 3 CN). The flow was 1 mL/min under isocratic conditions of 85 % CH 3 CN. The products were detected by following absorbance at 260nm wavelength.
Synthesis of O-Boc-bisdeoxycoelenterazine (8).Bisdeoxycoelenterazine
was dissolved in 0.5 mL pyridine. Under argon ditert butyl dicarbonate (59 μl, 0.256 mmol, 10 eq) was added and the reaction mixture stirred for 30 min. The solvent was removed in vacuo and the product isolated by column chromatography with ethyl acetate as eluent. 
Synthesis of acetoxymethyl-bisdeoxycoelenterazine(9).
To the mixture of bisdeoxycoelenterazine (10 mg, 25.6 μmol, 1 eq) in 1 mL pyridine were added 13 μL bromomethylacetate (0.13 mmol, 5 eq) and mixture stirred under argon. After usual work-up and purification, 6.6 mg product was isolated (57.6% yield). 1 Synthesis of pivaloyloxymethyl-bisdeoxycoelenterazine (10) 2 .Under argon, to the mixture containing bisdoexycoelenterazine (39.1 mg, 0.1 mmol, 1 eq), potassium carbonate (4.3 mg, 0.03 mmol, 0.03 eq) and chloromethylpivalate (144 μL, 1 mmol, 10eq) in 400 μL anhydrous DMF was added potassium iodide (17 mg, 0.1 mmol, of KI (17 mg, 0.1 mmol, 1 eq) and mixture stirred overnight. Water was added to the mixture and product extracted with ethyl acetate. Column chromatography with ethyl acetate as eluent afforded 12.5 mg product (24.7 %). 1 Luminescence measurements. Human fibrosracoma cell line HT1080 stably expressing GFP 2 -RLuc8 fusion protein was grown in Dulbecco's modified Eagle high glucose medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 1% penicillinstreptomycin and 500 μg/mL Zeocin TM (Invitrogen). One day before the luminescence study, 10 000 cells were plated in the 96 well plates (Corning Incorporated, Lowell, MA). After the removal of the medium 100 μL of the 5 μM solution of BDC in PBS and 60 μM solution of BDC derivatives in DMSO were added and luminescence measured every five minutes during one hour using an open filter setting. The acquisition time was 10 sec. Images were acquired using a cooled charged-coupled device (CCD) camera IVIS 50 (Caliper Life Sciences, Hopkinton, MA) and analyzed using Living Image ® software version 2.50.1 (Caliper Life Sciences, Hopkinton, MA). Region of interest were drawn, and maximum radiance used as the measure of luminescence. The measurements were done in triplicates.
Western blot analysis. Human fibrosracoma HT1080 cells (0.5 million) stably expressing GFP 2 -RLuc8 fusion protein were plated in the 6 well plates. One day after, the medium was removed and cells exposed to 2 mL 60 μM of BDC and its derivatives in DMEM medium that was not supplemented with FBS. As a control to one of the wells no RLuc substrates were added. After specific time points (1 hour and 24 hours) the S5 medium was removed, cells were washed with ice-cold phosphate buffered saline (PBS) once and lysed in 1X passive lysis buffer (Promega, Madison, WI) for 10 minutes on ice. After centrifugation at 13500 rpm for 15 minutes at 4 o C, protein content was determined using Bradford assay (Biorad, Hercules, CA) . 15 μg of total protein were resolved using the 4-12% NU-PAGE gradient gel (Invitrogen, Carlsbad, CA) and electroblotted onto nitrocellulose membrane (Schleicher & Schuell, Keene, NH) . The membrane was first incubated with blocking buffer (5% non fat dry milk in Tris-Buffered saline containing 0.01% Tween 20 (TBST)) for one hour, and then overnight at 4 o C with mouse monoclonal RLuc antibody (Milipore, Billerica, MA) 1000 times diluted in blocking buffer. The membrane was washed three times with TBST and incubated with peroxidase conjugated anti-mouse IgG (1:3000 dilution in the blocking buffer) for one hour. As a loading control, the membrane was incubated with the monoclonal anti-human α tubulin antibody (1:5000 dilution in the blocking buffer). Enhanced chemiluminescent method was used for visualization of protein bands. Figure S9 . Western blot analysis of GFP 2 -Rluc8 protein in the cells exposed to Rluc substrates for different amount of time.
The results of the protein expression analysis indicate that the light output at different time points depends on the rate of the bioluminescent reaction of a particular substrate and not on the level of GFP2-RLuc8 fusion protein expression. In addition, comparison with the protein level in the cells that have not been exposed to any of the substrates showed that none of the substrates have had any observable effect on the expression of the fusion protein, even at long exposure times.
